There are clinical stage investors all over the world in myriad companies that are frustrated by the FDA's movement like molasses. Regulators set the timeline and nothing can be done about that. The last thing the FDA wants to do is give investors any hope that cards, letters or angry emails could expedite things because then they would really get an onslaught.

The questions with any pending regulatory issue are whether the problem is solvable and is management working on it. Cyrus' exasperated laugh during the spring call let us know that he felt it should have been solved already, so the answer to the former is likely yes, and there's been nothing to indicate that management has been remiss in their duties so all we can do is wait.